*仅供医学专业人士阅读参考
直击2024 SABCS，见证乳腺癌治疗革新
撰文 | lily
2024年12月10日-13日，第47届圣安东尼奥乳腺癌研讨会（SABCS）将在美国圣安东尼奥隆重举行。作为乳腺癌研究领域中规模最大、最具盛名的科学聚会之一，SABCS大会集结了近一年来乳腺癌领域的最新研究成果、临床实践经验、治疗进展和技术创新等内容。
日前，大会公布了摘要标题。医学界特对LBA Oral Session、General Session、Rapid Fire Session的口头报告研究进行整理，涉及围手术期治疗、症状监测、基因检测、风险评估等多项拓展分析研究，以供读者参考。
围手术期相关研究
LBA Oral Session
摘要号：LB1-01
Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women.
可手术乳腺癌不立即手术或手术范围缩小的长期影响：对2,514名女性的四项随机试验的患者水平荟萃分析。
讲者：Robert Hills, University of Oxford, Oxford, United Kingdom
General Session
摘要号：GS1-08
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study.
降低风险手术与携带BRCA突变的年轻乳腺癌患者生存情况的关系：一项国际队列研究的结果
讲者：Matteo Lambertini, University of Genova, Genova, Italy
摘要号：GS2-02
Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
仅在“低风险”的乳腺导管原位癌患者接受保乳术后使用他莫昔芬治疗的影响：来自NRG Oncology/RTOG 9804和ECOG-ACRIN E5194试验的结果
讲者：Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina
摘要号：GS2-03
Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators.
在“中危”乳腺癌患者接受术后放疗是否影响总生存期？BIG 2-04 MRC SUPREMO随机试验的10年结果：来自SUPREMO试验研究者。
讲者：Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland
摘要号：GS2-05
Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
低风险导管原位癌（DCIS）患者接受积极监测或手术（±放疗）的早期肿瘤学结果：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）
讲者：Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina
摘要号：GS2-06
Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
DCIS患者接受积极监测或手术（±放疗）后的患者报告结果：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）
讲者：Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts
摘要号：GS2-07
No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
接受保乳术的早期浸润性乳腺癌患者无腋窝清扫vs腋窝前哨淋巴结活检：Intergroup-Sentinel-Mamma（INSEMA）试验的最终主要结果。
讲者：Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany
Rapid Fire Session
摘要号：RF2-01
Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.
在Alliance A011202临床试验入组患者中，分析影响新辅助化疗后残留腋窝淋巴结阳性乳腺癌患者的淋巴结病变以及病理淋巴结分期上调的腋窝淋巴结清扫相关因素。
讲者：Judy Boughey, Mayo Clinic, Rochester, Minnesot
摘要号：RF2-02
Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.
早期乳腺癌患者接受新辅助全身治疗（NST）后的腋窝手术：5项新辅助治疗研究中残留微转移的治疗路径和预后影响。
讲者：Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH
摘要号：RF2-03
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).
新辅助化疗后初诊腋窝淋巴结阳性的乳腺癌患者行腋窝超声的诊断效能：来自前瞻性AXSANA注册试验（NCT04373655）的结果。
讲者：Steffi Hartmann, University of Rostock, Rostock, Germany
摘要号：RF3-06
Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy: Results from Alliance A221803: A Multicenter Phase III Randomized Clinical Trial
美菲膜（mepitel film）用于乳房切除术后放疗期间以减少放射性皮炎：来自多中心、III期随机临床试验Alliance A221803的结果。
讲者：Kimberly Corbin, Mayo Clinic, Rochester, Minnesota
摘要号：RF3-07
ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy.
ROSCO研究：可手术乳腺癌新辅助化疗最佳选择的疗效反应：一项比较5-氟尿嘧啶、表柔比星和环磷酰胺 vs 多西他赛联合环磷酰胺新辅助化疗的随机III期、分层生物标志物试验。
讲者：Daniel Rea, University of Birmingham, Birmingham, United Kingdom
症状监测与拓展分析
General Session
摘要号：GS1-06
PRO B–a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients.
PROB研究——一项评估转移性乳腺癌患者症状监测效果的优越性随机对照试验。
讲者：Maria Margarete Karsten, Charité-Universitätsmedizin, Berlin
摘要号：GS2-09
Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
早期乳腺癌试验协作组（EBCTCG）数据库中206,904名女性超重、肥胖和预后情况
讲者：Hongchao Pan, University of Oxford, Oxford, United Kingdom
摘要号：GS2-10
A long-term image-derived AI risk model for primary prevention of breast cancer.
一种用于乳腺癌一级预防的长期图像衍生AI风险模型。
讲者：Mikael Eriksson, Karolinska Institutet, Solna, Sweden
摘要号：GS2-11
APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.
APOBEC3突变诱导乳腺癌促耐药性基因组改变。
讲者：Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York
摘要号：GS3-08
In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss.
对乳腺癌中单个经典MHC-I基因产物的原位检测，以识别基因和亚型特异性的偏倚抗原呈递丢失。
讲者：Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Rapid Fire Session
摘要号：RF1-01
Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance).
减重干预（WLI）对肥胖乳腺癌女性的代谢和炎症生物标志物的影响：乳腺癌减重（BWEL）试验（联盟）的结果。
讲者：Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, Massachusetts
摘要号：RF1-05
DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.
同侧与对侧乳房的良性组织中DNA甲基化模式相似，但与配对的乳腺癌组织和健康对照组不同。
讲者：Saya Dennis, Northwestern University Feinberg School of Medicine, Chicago, Illinois
摘要号：RF1-06
Association of polygenic-based breast cancer risk prediction with patient management.
基于多基因风险评估的乳腺癌预测与患者管理的相关性。
讲者：Katie Johansen Taber, Myriad Genetics, San Francisco, California
摘要号：RF1-07
Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
度伐利尤单抗、曲妥珠单抗联合帕妥珠单抗无化疗方案（DTP试验）治疗HER2富集型早期乳腺癌的病理完全缓解（pCR）多因素分析。
讲者：Bojana Stefanovska, UT Health Science Center, San Antonio, Texas
摘要号：RF2-05
Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study.
淋巴结阳性乳腺癌患者的TILs、ER状态与放疗获益的相关性验证：DBCG研究。
讲者：Demet Özcan, Aarhus University Hospital, Aarhus, Denmark
摘要号：RF2-06
A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.
在NCORP社区实践中，探讨奥氮平vs丙氯拉嗪治疗时出现化疗导致的难治性恶心的一项全国性、双盲、III期、随机对照试验（RCT）。
讲者：Luke Peppone, University of Rochester Medical Center, Rochester, New York
精彩资讯等你来
责任编辑：Sheep
*医学界力求其发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。